Global travel vaccine market is expected to reach USD 13,087,835.81 thousand by 2032 from USD 6,144,158.80 thousand in 2023, growing at a substantial CAGR of 8.9% in the forecast period of 2024 to 2032.
Market Segmentation:
Global travel vaccines market, By Composition (Combination Vaccines and Mono Vaccines), Type (Inactivated Vaccines, Subunit, Recombinant, Polysaccharide and Conjugate Vaccines, Live-Attenuated Vaccines, Toxoid Vaccines, DNA Vaccines, and Viral Vector Vaccines), Category (Recommended Vaccine, Routine Vaccine, and Required Vaccine), Disease (Typhoid, Hepatitis, Cholera, Varicella, Influenza, Japanese Encephalitis, Meningococcal Meningitis, Yellow Fever, Rabies, DPT, Measles and Mumps, Tick-Borne Encephalitis, Malaria, Covid-19, Polio, and Others), Route of Administration (Injectable and Oral), Gender (Male and Female), Patient Type (Adult, Pediatric, and Geriatric), Age Group (20-50 Years, Less than 20 Years, and Above 50 Years), Distribution Channel (B2B and B2C), Countries (U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Poland, Norway, Hungary, Austria, Ireland, Lithuania, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, Kuwait, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032
Some of the major factors contributing to the growth of the global travel vaccines market are:
- Driver
- Rising incidence of infectious diseases
- Restraint
- High cost of travel vaccines
- Opportunity
- Advancements in vaccine technology
Market Players
Some major companies dealing in the global travel vaccines market are:
- GSK plc.
- Bavarian Nordic
- Pfizer Inc.
- Abbott
- CSL
- AstraZeneca
- Sanofi
- Merck & Co., Inc.
- Valneva SE
- Johnson & Johnson Services Inc.
- Dynavax Technologies.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 OBJECTIVES OF THE STUDY
- 1.2 MARKET DEFINITION
- 1.3 OVERVIEW OF GLOBAL TRAVEL VACCINES MARKET
- 1.4 LIMITATIONS
- 1.5 MARKETS COVERED
2 MARKET SEGMENTATION
- 2.1 MARKETS COVERED
- 2.2 GEOGRAPHICAL SCOPE
- 2.3 YEARS CONSIDERED FOR THE STUDY
- 2.4 CURRENCY AND PRICING
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL
- 2.6 MULTIVARIATE MODELLING
- 2.7 PRODUCT TYPE LIFELINE CURVE
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.9 DBMR MARKET POSITION GRID
- 2.10 MARKET APPLICATION COVERAGE GRID
- 2.11 VENDOR SHARE ANALYSIS
- 2.12 SECONDARY SOURCES
- 2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 PESTEL ANALYSIS
- 4.2 PORTER'S FIVE FORCES
- 4.3 PIPELINE ANALYSIS
5 MARKET OVERVIEW
- 5.1 DRIVERS
- 5.1.1 RISING INCIDENCE OF INFECTIOUS DISEASES
- 5.1.2 INCREASING TRAVEL AND TOURISM
- 5.1.3 GOVERNMENT REGULATIONS AND RECOMMENDATIONS REGARDING VACCINATION
- 5.1.4 EXPANSION OF TRAVEL MEDICINE CLINICS
- 5.2 RESTRAINTS
- 5.2.1 HIGH COST OF TRAVEL VACCINES
- 5.2.2 REGULATORY HURDLES FOR APPROVAL
- 5.3 OPPORTUNITIES
- 5.3.1 ADVANCEMENTS IN VACCINE TECHNOLOGY
- 5.3.2 GROWING AWARENESS REGARDING VACCINES
- 5.3.3 INTEGRATION OF DIGITAL HEALTH SOLUTIONS
- 5.4 CHALLENGES
- 5.4.1 COLD CHAIN REQUIREMENTS FOR STORAGE
- 5.4.2 VACCINE HESITANCY AND MISINFORMATION
6 GLOBAL TRAVEL VACCINE MARKET, BY COMPOSITION
- 6.1 OVERVIEW
- 6.2 COMBINATION VACCINES
- 6.3 MONO VACCINES
7 GLOBAL TRAVEL VACCINE MARKET, BY TYPE
- 7.1 OVERVIEW
- 7.2 INACTIVATED VACCINES
- 7.2.1 HEPATITIS A
- 7.2.2 INFLUENZA
- 7.2.3 RABIES
- 7.2.4 TICK-BORNE ENCEPHALITIS
- 7.2.5 JAPANESE ENCEPHALITIS
- 7.2.6 POLIO
- 7.3 SUBUNIT, RECOMBINANT, POLYSACCHARIDE AND CONJUGATE VACCINES
- 7.3.1 HEPATITIS B
- 7.3.2 MENINGOCOCCAL
- 7.3.3 MALARIA
- 7.3.4 COVID-19
- 7.4 LIVE-ATTENUATED VACCINES
- 7.4.1 TYPHOID
- 7.4.2 CHOLERA
- 7.4.3 YELLOW FEVER
- 7.4.4 MEASLES
- 7.4.5 MUMPS
- 7.4.6 RUBELLA
- 7.4.7 VARICELLA
- 7.4.8 OTHERS
- 7.5 TOXOID VACCINES
- 7.5.1 DIPHTHERIA
- 7.5.2 TETANUS
- 7.6 DNA VACCINES
- 7.7 VIRAL VECTOR VACCINES
8 GLOBAL TRAVEL VACCINE MARKET, BY CATEGORY
- 8.1 OVERVIEW
- 8.2 RECOMMENDED VACCINE
- 8.2.1 TYPHOID FEVER VACCINES
- 8.2.2 HEPATITIS A
- 8.2.3 CHOLERA
- 8.2.4 RABIES
- 8.2.5 TICK-BORNE ENCEPHALITIS
- 8.2.6 JAPANESE ENCEPHALITIS
- 8.2.7 MALARIA
- 8.2.8 OTHERS
- 8.3 ROUTINE VACCINE
- 8.3.1 HEPATITIS B
- 8.3.2 INFLUENZA VACCINES
- 8.3.3 PNEUMOCOCCAL
- 8.3.4 DIPHTHERIA
- 8.3.5 TETANUS
- 8.3.6 MEASLES
- 8.3.7 MUMPS
- 8.3.8 RUBELLA
- 8.3.9 PERTUSSIS
- 8.3.10 OTHERS
- 8.4 REQUIRED VACCINE
- 8.4.1 YELLOW FEVER
- 8.4.2 MENINGOCOCCAL
- 8.4.3 POLIO VACCINES
9 GLOBAL TRAVEL VACCINE MARKET, BY DISEASE
- 9.1 OVERVIEW
- 9.2 TYPHOID
- 9.3 HEPATITIS
- 9.3.1 HEPATITIS A
- 9.3.2 HEPATITIS B
- 9.4 CHOLERA
- 9.5 VARICELLA
- 9.6 INFLUENZA
- 9.7 JAPANESE ENCEPHALITIS
- 9.8 MENINGOCOCCAL MENINGITIS
- 9.9 YELLOW FEVER
- 9.10 RABIES
- 9.11 DPT
- 9.12 MEASLES AND MUMPS
- 9.13 TICK-BORNE ENCEPHALITIS
- 9.14 MALARIA
- 9.15 COVID-19
- 9.16 POLIO
- 9.17 OTHERS
10 GLOBAL TRAVEL VACCINE MARKET, BY ROUTE OF ADMINISTRATION
- 10.1 OVERVIEW
- 10.2 INJECTABLE
- 10.2.1 INTRAMUSCULAR
- 10.2.2 SUBCUTANEOUS
- 10.2.3 OTHERS
- 10.3 ORAL
11 GLOBAL TRAVEL VACCINE MARKET, BY GENDER
- 11.1 OVERVIEW
- 11.2 MALE
- 11.3 FEMALE
12 GLOBAL TRAVEL VACCINE MARKET, BY PATIENT TYPE
- 12.1 OVERVIEW
- 12.2 ADULT
- 12.3 PEDIATRIC
- 12.4 GERIATRIC
13 GLOBAL TRAVEL VACCINE MARKET, BY AGE GROUP
- 13.1 OVERVIEW
- 13.2 20-50 YEARS
- 13.3 LESS THAN 20 YEARS
- 13.4 ABOVE 50 YEARS
14 GLOBAL TRAVEL VACCINE MARKET, BY DISTRIBUTION CHANNEL
- 14.1 OVERVIEW
- 14.2 B2B
- 14.3 B2C
15 GLOBAL TRAVEL VACCINE MARKET, BY REGION
- 15.1 OVERVIEW
- 15.2 NORTH AMERICA
- 15.2.1 U.S.
- 15.2.2 CANADA
- 15.2.3 MEXICO
- 15.3 ASIA-PACIFIC
- 15.3.1 INDIA
- 15.3.2 CHINA
- 15.3.3 MALAYSIA
- 15.3.4 SOUTH KOREA
- 15.3.5 JAPAN
- 15.3.6 AUSTRALIA
- 15.3.7 THAILAND
- 15.3.8 VIETNAM
- 15.3.9 SINGAPORE
- 15.3.10 INDONESIA
- 15.3.11 PHILIPPINES
- 15.3.12 REST OF ASIA-PACIFIC
- 15.4 EUROPE
- 15.4.1 GERMANY
- 15.4.2 U.K.
- 15.4.3 FRANCE
- 15.4.4 RUSSIA
- 15.4.5 ITALY
- 15.4.6 SPAIN
- 15.4.7 POLAND
- 15.4.8 NETHERLANDS
- 15.4.9 SWITZERLAND
- 15.4.10 HUNGARY
- 15.4.11 AUSTRIA
- 15.4.12 IRELAND
- 15.4.13 NORWAY
- 15.4.14 LITHUANIA
- 15.4.15 REST OF EUROPE
- 15.5 MIDDLE EAST AND AFRICA
- 15.5.1 SAUDI ARABIA
- 15.5.2 EGYPT
- 15.5.3 SOUTH AFRICA
- 15.5.4 KUWAIT
- 15.5.5 U.A.E.
- 15.5.6 ISRAEL
- 15.5.7 REST OF MIDDLE EAST AND AFRICA
- 15.6 SOUTH AMERICA
- 15.6.1 ARGENTINA
- 15.6.2 BRAZIL
- 15.6.3 PERU
- 15.6.4 REST OF SOUTH AMERICA
16 GLOBAL TRAVEL VACCINE MARKET: COMPANY LANDSCAPE
- 16.1 COMPANY SHARE ANALYSIS: GLOBAL
- 16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
- 16.3 COMPANY SHARE ANALYSIS: EUROPE
- 16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17 SWOT ANALYSIS
18 COMPANY PROFILE
- 18.1 PFIZER INC.
- 18.1.1 COMPANY SNAPSHOT
- 18.1.2 REVENUE ANALYSIS
- 18.1.3 COMPANY SHARE ANALYSIS
- 18.1.4 PRODUCT PORTFOLIO
- 18.1.5 RECENT DEVELOPMENT
- 18.2 SANOFI
- 18.2.1 COMPANY SNAPSHOT
- 18.2.2 REVENUE ANALYSIS
- 18.2.3 COMPANY SHARE ANALYSIS
- 18.2.4 PRODUCT PORTFOLIO
- 18.2.5 RECENT DEVELOPMENT
- 18.3 JOHNSON & JOHNSON SERVICES INC.
- 18.3.1 COMPANY SNAPSHOT
- 18.3.2 REVENUE ANALYSIS
- 18.3.3 COMPANY SHARE ANALYSIS
- 18.3.4 PRODUCT PORTFOLIO
- 18.3.5 RECENT DEVELOPMENTS
- 18.4 GSK PLC.
- 18.4.1 COMPANY SNAPSHOT
- 18.4.2 REVENUE ANALYSIS
- 18.4.3 COMPANY SHARE ANALYSIS
- 18.4.4 PRODUCT PORTFOLIO
- 18.4.5 RECENT DEVELOPMENT
- 18.5 MERCK & CO., INC.
- 18.5.1 COMPANY SNAPSHOT
- 18.5.2 REVENUE ANALYSIS
- 18.5.3 COMPANY SHARE ANALYSIS
- 18.5.4 PRODUCT PORTFOLIO
- 18.5.5 RECENT DEVELOPMENT
- 18.6 ABBOTT
- 18.6.1 COMPANY SNAPSHOT
- 18.6.2 REVENUE ANALYSIS
- 18.6.3 PRODUCT PORTFOLIO
- 18.6.4 RECENT DEVELOPMENT
- 18.7 ASTRAZENECA
- 18.7.1 COMPANY SNAPSHOT
- 18.7.2 REVENUE ANALYSIS
- 18.7.3 PRODUCT PORTFOLIO
- 18.7.4 RECENT DEVELOPMENT
- 18.8 BAVARIAN NORDIC
- 18.8.1 COMPANY SNAPSHOT
- 18.8.2 REVENUE ANALYSIS
- 18.8.3 PRODUCT PORTFOLIO
- 18.8.4 RECENT DEVELOPMENT
- 18.9 CSL
- 18.9.1 COMPANY SNAPSHOT
- 18.9.2 REVENUE ANALYSIS
- 18.9.3 PRODUCT PORTFOLIO
- 18.9.4 RECENT DEVELOPMENT
- 18.10 DYNAVAX TECHNOLOGIES.
- 18.10.1 COMPANY SNAPSHOT
- 18.10.2 REVENUE ANALYSIS
- 18.10.3 PRODUCT PORTFOLIO
- 18.10.4 RECENT DEVELOPMENTS
- 18.11 VALNEVA SE
- 18.11.1 COMPANY SNAPSHOT
- 18.11.2 REVENUE ANALYSIS
- 18.11.3 PRODUCT PORTFOLIO
- 18.11.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS